This course is designed to share with participants recent experiences in the production, quality control and preclinical evaluation of emerging cyclotron-based radiopharmaceuticals. This will include, but not limited to, F-18 (beyond F-18 FDG) as well as metallic (e.g. Cu-64 and Zr-89) radiopharmaceuticals.
The course will be held at ANSTO, Lucas Heights, Australia.
Registration
Please register your intention to attend this course by completing the registration form as soon as possible.
Registration includes:
- 5 days training program
- 6 night's accommodation at Rydges Hotel Cronulla
- Check in Sunday 15 October
- Check out Saturday 21 October
- Return bus transport from the Hotel to ANSTO each day
- Lunch each day
- Tour of ANSTO facilities
- Tour to Royal North Shore Hospital
- Training group dinner on Thursday 19th October
Register here
The Program
Expected Outputs
By the end of this course, participants are expected to understand the basic concepts and challenges for establishing the production of various emerging cyclotron-based radiopharmaceuticals for future clinical applications in their countries. Interesting examples and cases studies will be drawn from F-18 radiopharmaceuticals (beyond FDG), as well as new metal-based positron emitter radiopharmaceuticals (e.g. Cu-64, Zr-89 radionuclides). The design and execution of preclinical studies will also be presented with a tour of a preclinical facility.
Scope
The training course will be centred on the production and quality control of emerging cyclotron-based radiopharmaceuticals with consideration of equipment and important parameters such as chemicals used, radioisotope purity and molar activity that are suitable for preclinical studies and translation to first in human evaluation.
The content will be delivered in the form of lectures, interactive discussion sessions and guided tours of related facilities.
For more information
